Healthcare Industry News: radiosurgery
News Release - May 24, 2017
Accuray Appoints Stan Gee VP of Revenue ManagementSUNNYVALE, Calif., May 24, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed, Stan Gee, who has been with Accuray for over eight years, to the newly created Vice President of Revenue Management position reporting to Kevin Waters, Chief Financial Officer. Mr. Gee will be responsible for driving the global revenue forecast and overseeing the order to revenue conversion process for the Company. In his new role, Mr. Gee will be working closely with Accuray's customers, regional installation, service and commercial teams to improve the overall timing and cadence of system installation and ultimately revenue conversion, specifically in those regions where distributor initiated orders have become a bigger part of the overall order mix in backlog.
"During his eight-year career with Accuray, Stan has proven to be an exceptional leader and has developed a reputation within our organization for meeting objectives and achieving results," said Mr. Waters. "We have a high degree of confidence he will lead our new initiatives in revenue management and conversion with a renewed sense of urgency and focus."
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to Accuray's company trajectory, including without limitation the anticipated impact on the company's ability to convert backlog into revenue, and Accuray's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsHong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact(R) System and ClearRT(TM) Helical Fan-Beam kVCT Imaging
Accuray Expands CyberKnife(R) System Versatility with Integration of RaySearch's RayStation Treatment Planning System
RayStation Latest Release, Now with Support for Accuray's CyberKnife(R) System